Estimates of the Prevalence of Autism Spectrum Disorder in the Middle East and North Africa Region: A Systematic Review and Meta-Analysis - Akomolafe, Aishat F.; Abdallah, Bushra M.; Mahmood, Fathima R.; Elshoeibi, Amgad M.; Al-Khulaifi, Aisha Abdulla; Mahmoud, Elhassan; Dweidri, Yara; Darwish, Nour; Yousif, Duaa; Khalid, Hafsa; Al-Theyab, Majed; Azeem, Muhammad Waqar; et al. (medRxiv, 2024)
Background and Objective Estimates of the prevalence of the autism spectrum disorder (ASD) in the Middle East and North Africa (MENA) region are not readily available, amid a lack of recent evidence. In this study, we estimated the prevalence of ASD in the MENA region by synthesising evidence from published studies in the region.Methods In this systematic review and meta-analysis, we searched PubMed, EMBASE, Scopus, and CINAHL databases for studies which assessed ASD prevalence in the MENA region. Risk of bias was assessed using the Newcastle Ottawa scale. A bias-adjusted inverse variance heterogeneity meta-analysis model was used to pool prevalence estimates from included studies. Cochran’s Q statistic and the I2 statistic were used to assess heterogeneity, and publication bias assessed using funnel and Doi plots.Results A total of 3075 studies were identified, 16 studies of which met the inclusion criteria and involved 3,727,731 individuals. The studies were published during the period 2007-2022, and included individuals from Iran, Oman, Libya, Egypt, Kingdom of Saudi Arabia (KSA), Lebanon, United Arab Emirates (UAE), Bahrain and Qatar. Estimates of ASD prevalence ranged from 0.01% in Oman during the period June 2009-December 2009, to a high of 2.51% in the Kingdom of Saudi Arabia during the period December 2017-March 2018. The pooled prevalence of ASD was 0.13% (95% CI: 0.01% – 0.33%), with significant heterogeneity (I2 = 99.8%). For Iran, the only country with multiple analysable studies, an overall prevalence of 0.06% (95% CI: 0.00 – 0.19, I2=97.5%, n= 6 studies) was found. A review of data from countries with repeated studies suggested that the prevalence of ASD is increasing.Conclusion Estimates of the prevalence of ASD vary widely across the MENA region, from 0.01% in Oman to 2.51% in Saudi, with an overall prevalence of 0.13%. Existing data suggests a trend towards increasing prevalence in the region. More and better-quality research is needed to provide up to date ASD prevalence estimates.Registration The protocol for this systematic review and meta-analysis was registered on the International Prospective Register of Systematic Reviews (PROSPERO) with registration ID CRD42024499837.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Qatar National Research Fund, Undergraduate Research Experience Program (UREP) (Grant ID: UREP30-211-3-073). Open Access Funding provided by the Qatar National Library.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis study is a meta-analysis of published studies and the data used in this work are prevalence rates from the included studies. The availability of the underlying individual participant data is subject to the primary publications’ journal policies.